GoodRx Holdings, Inc. (NASDAQ:GDRX) Stock Has Average Price Target of $4.23

Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) have been given a consensus recommendation of “Hold” by the thirteen ratings firms that are currently covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a sell recommendation, six have given a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $4.23.

Several analysts have weighed in on the stock. UBS Group boosted their price target on shares of GoodRx from $2.50 to $3.75 and gave the stock a “neutral” rating in a research note on Thursday, August 13th. Wall Street Zen upgraded GoodRx from a “hold” rating to a “buy” rating in a report on Saturday, August 15th. The Goldman Sachs Group reissued a “neutral” rating and issued a $4.00 target price on shares of GoodRx in a research note on Friday, August 7th. Barclays increased their target price on GoodRx from $3.00 to $4.00 and gave the company an “underweight” rating in a report on Thursday, August 20th. Finally, Weiss Ratings raised GoodRx from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, August 7th.

GoodRx Stock Up 2.4%

Shares of GDRX opened at $3.36 on Friday. GoodRx has a 1 year low of $1.77 and a 1 year high of $5.81. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.38 and a quick ratio of 1.38. The stock has a 50 day simple moving average of $3.44 and a two-hundred day simple moving average of $2.89. The firm has a market cap of $1.15 billion, a P/E ratio of 84.02, a P/E/G ratio of 1.63 and a beta of 1.69.

GoodRx (NASDAQ:GDRX) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.08 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.08. GoodRx had a net margin of 2.07% and a return on equity of 7.22%. The firm had revenue of $200.41 million during the quarter, compared to analyst estimates of $193.23 million. During the same period in the previous year, the business posted $0.09 EPS. The business’s quarterly revenue was down 1.3% on a year-over-year basis. On average, analysts forecast that GoodRx will post 0.16 earnings per share for the current fiscal year.

Insider Activity at GoodRx

In related news, major shareholder Francisco Partners Iv, L.P. sold 1,296,177 shares of the company’s stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $3.50, for a total transaction of $4,536,619.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have sold 2,760,995 shares of company stock valued at $9,673,207 over the last quarter. 5.87% of the stock is owned by insiders.

Institutional Investors Weigh In On GoodRx

Large investors have recently added to or reduced their stakes in the company. Headlands Technologies LLC purchased a new position in shares of GoodRx in the second quarter worth $30,000. Essential Partners LLC boosted its position in shares of GoodRx by 375.4% during the first quarter. Essential Partners LLC now owns 14,304 shares of the company’s stock valued at $28,000 after buying an additional 11,295 shares during the last quarter. SG Americas Securities LLC bought a new stake in GoodRx in the 1st quarter worth about $29,000. Krilogy Financial LLC bought a new stake in GoodRx in the 1st quarter worth about $33,000. Finally, Amundi purchased a new position in GoodRx in the 1st quarter worth about $37,000. Institutional investors own 63.77% of the company’s stock.

GoodRx Company Profile

GoodRx Holdings, Inc operates a healthcare technology platform that helps consumers find prescription medications at lower prices. Through its website and mobile applications, GoodRx allows users to compare prescription prices at participating pharmacies, access discount coupons and identify potential savings on commonly prescribed medications. The company’s services are primarily focused on the United States.

GoodRx also offers GoodRx Gold, a membership program that provides additional discounts on eligible prescriptions, as well as telehealth services that connect consumers with healthcare providers for certain medical consultations and prescriptions.